ArticleGland surgery2025
Risk factors and predictive nomograms for early mortality in patients with thyroid cancer lung metastasis based on the SEER database and a Chinese population study.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lung is the most vulnerable site for distant thyroid cancer (TC) metastasis, and individuals who have TC lung metastases (TCLMs) succumb to the illness shortly after diagnosis. This study aims to identify the risk factors of early mortality in TCLM patients and develop a reliable and accurate prediction model. An accurate nomogram for predicting early mortality (survival time ≤3 months) in TCLM patients is necessary. Methods: Between 2010 and 2015, information gathered from TCLM patients in the Surveillance, Epidemiology, and End Results (SEER) database was used to develop and internally evaluate a prediction model. External validation was performed using data acquired from a Chinese population. All-cause early death (ACED) encompassed mortality from any cause within this period, whereas cancer-specific early death (CSED) specifically referred to deaths explicitly attributed to TC or its complications on the death certificate. The risk factors for CSED and ACED were identified independently using univariate and multivariable logistic regressions. The nomogram's accuracy was confirmed via receiver operating characteristic (ROC) curve analysis, and calibration curves were used to evaluate the consistency between the model predictions and the actual outcomes. Decision curve analysis (DCA) was performed to assess the model's clinical applicability. Results: This study included 945 patients, 636 (67.3%) of whom died shortly after diagnosis and 335 (35.4%) of whom died from TCLM-related complications. Multivariable logistic regression analyses independently identified six predictors for ACED and seven predictors for CSED. The areas under the curve (AUCs) of the nomogram for predicting ACED and CSED were 0.912 [95% confidence interval (CI): 0.889-0.931] and 0.732 (95% CI: 0.691-0.776), respectively. Combined with the results of the calibration curve analysis, these findings demonstrated that the nomograms effectively predicted the risk of early death in both the internal and external sets. DCA revealed that the nomograms provide considerable clinical advantages. Conclusions: In the present study, nomograms were developed to reliably predict the risk of early mortality in individuals with TCLM. These tools can assist physicians in identifying high-risk patients and implementing tailored treatment plans as soon as possible.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.